We found that the compound-mediated cytotoxic effect against colon cancer cells was greatly improved by the concomitant inhibition of NRF2 and BiP, highlighting a critical interplay between these two molecules and their pathways that cancer cells exploit to resist to the cytotoxic effect of the anticancer therapies. This evidence concerns the gene HSPA5 and cancer.